Rabeprazole Sodium SaltA proton pump inhibitor

Rabeprazole Sodium Salt (CAS 117976-90-6)

Rabeprazole Sodium Salt | CAS 117976-90-6 is rated 5.0 out of 5 by 1.
  • y_2019, m_9, d_23, h_9
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_208255, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 89ms
  • REVIEWS, PRODUCT
Synonym: 2-[[[4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole, Sodium Salt; Pariet
Application: A proton pump inhibitor
CAS Number: 117976-90-6
Purity: ≥99%
Molecular Weight: 381.43
Molecular Formula: C18H20N3NaO3S
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Rabeprazole Sodium Salt is a partially reversible gastric proton pump inhibitor. Rabeprazole Sodium Salt is an inhibitor of ATP4.


References

Morii, M., and Takeguchi, N.: J. Biol. Chem., 268, 21553 (1993), Yasuda, S., et al.: Int. J. Clin. Pharmacol. Ther., 32, 466 (1994), Cloud, M.L., et al.: Dig. Dis. Sci., 43, 993 (1998)

Appearance :
Crystalline
Physical State :
Solid
Solubility :
Soluble in water (10 mg/ml), methanol, DMSO (~25 mg/ml), DMF (~30 mg/ml), and ethanol (~30 mg/ml).
Storage :
Desiccate at 4° C
Melting Point :
140-141° C (dec.)
Refractive Index :
n20D ~1.65 (Predicted)
IC50 :
Gastric H+/K+ ATPase pump: IC50 = 72 nM; H. pylori: IC50 = 0.29 µM
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
RTECS :
DD9098600
PubChem CID :
14720269
MDL Number :
MFCD02092688
EC Number :
222-630-7
Beilstein Registry :
7561607
SMILES :
COCCCOC1=CC=NC(CS(=O)C2=NC3=C(C=CC=C3)N2[Na])=C1C

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 56ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Moody DE; et al Moody DE; et al. (PubMed ID: 23857299) determined that Rabeprazole Sodium Salt pre-incubation with cytochrome P450 increased the inhibition of noroxycodone and oxymorphone metabolism. -SCBT Publication Review
Date published: 2015-07-14
  • y_2019, m_9, d_23, h_9
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_208255, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 4ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.